Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: Knox County’s proposed ordinance hasn’t been drafted yet, but County Attorney Yvette Kirchoff said the ordinance wouldn’t be retroactive so homeowners won’t have to remove existing plants. If the measure is approved, Knox County would be the first in Indiana to move forward with such an ordinance, Kirchoff told the Vincennes Sun-Commercial . Invasive species can take over and alter environments, said Will Drews, a natural resource specialist with the Knox County Soil and Water Conservation District. They can also disrupt pasture lands and agriculture. “We’ve introduced most of them, unfortunately, over time,” he said. “They’re mostly from other parts of the world, such as Europe or Asia, and the problem is that they have no natural predators, so they just kind of get out of control.” One major issue is that some invasive species — such as wintercreeper, Japanese honeysuckle and burning bush — can be found in local nurseries and are used by landscapers, Drews said. “These are plants that are literally destroying our forests,” Drews said. “That’s frustrating to a lot of the folks that I work with and those who are aware of the problem.” The state Department of Natural Resources and state lawmakers have been working on legislation that would attempt to regulate the spread of invasive species, but the process has been slow, Drews said. Drews and Kirchoff are drafting the ordinance and will present it to the county commissioners soon. ___ Information from: Vincennes Sun-Commercial, http://www.vincennes.com

Answer: Indiana county working on invasive plants ordinance.


Question: Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). The highest trial dose was discontinued due to toxicity. Nearly a third of trial patients developed serious infections and other side effects included nerve damage and liver failure. Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration. “Based on these data, we plan to open an expanded trial,” David Reese, Amgen’s head of research and development, said in an interview. “We want to begin exploring quickly enrollment in earlier lines of therapy.”  Amgen’s pipeline of bispecific antibodies, which are designed to attach to a cancer cell and an immune cell, bringing them together so the body’s immune system can kill the cancer, are a cornerstone of the biotech company’s oncology research. Other companies are exploring different ways to attack the same BCMA target, including bluebird bio Inc, Celgene Corp and Johnson & Johnson. Earlier at the ASH meeting, bluebird and Celgene presented early trial data showing that experimental cell therapy bb21217 induced responses in 10 out of 12 heavily pre-treated myeloma patients. Bb21217 is a next-generation version of bb2121, the companies’ more advanced, but still experimental therapy in a class called CAR-T that requires harvesting a patient’s own disease-fighting T-cells, modifying them in a laboratory so they target specific proteins on cancer cells and infusing them back into the patient. The manufacturing process for bb21217 is designed to improve the persistence of the altered cells. J&J, which licensed BCMA-directed CAR-T LCAR-B38M from a unit of China-based GenScript Biotech Corp, on Monday presented updated results from a Chinese study of the cell therapy in 57 previously treated myeloma patients. It showed that 88 percent of patients responded to the treatment, and 74 percent achieved remission. J&J is currently enrolling patients in an international study aimed at validating those findings. Amgen has suggested the “off the shelf” nature of its antibody platform could be an advantage from both a clinical and commercial standpoint, but oncologists say more data is needed. Trial patients are hospitalized for their first cycle of AMG420, after which they receive the drug by continuous 24-hour infusion for four weeks, followed by two weeks off therapy, for up to 10 cycles. Amgen has another BCMA-targeting antibody that lasts longer in the body, requiring less frequent infusions, but that research is at an earlier stage. In the current study, 42 patients with multiple myeloma that  worsened after at least two prior treatments were given AMG420 at varying doses. A total of 13 patients responded to the treatment, including seven who achieved remission. Of the 20 patients with serious adverse events, 17 required hospitalization and four had prolonged hospitalization.

Answer: Amgen antibody shows promise in myeloma trial, gets FDA fast track.


Question: Brian and Kristen Festa, of Bristol, said Saturday they asked the department for a declaratory ruling on their petition because officials plan to release additional data this month. A Superior Court judge dismissed their lawsuit in September. The couple had sought to stop the release of additional immunization information and have school-by-school immunization data from 2017-18 removed online. The judge said they hadn’t exhausted their “administrative remedies” with public health officials. Parents of an unvaccinated son, Brian and Kristen Festa say they’ve suffered mental and emotional distress due to hateful statements from the public since the release of immunization rate data in May.

Answer:
Couple asks state for quick decision about vaccination data.